Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 52-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Time-Lagged, Parallel Group Study in Patients With Mild to Moderate Alzheimer's Disease (AD) to Investigate the Safety, Tolerability and A beta-Specific Antibody Response Following Three Subcutaneous Injections of CAD106

Next Previous
X
Search
Trial Profile

A 52-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Time-Lagged, Parallel Group Study in Patients With Mild to Moderate Alzheimer's Disease (AD) to Investigate the Safety, Tolerability and A beta-Specific Antibody Response Following Three Subcutaneous Injections of CAD106

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 02 Apr 2013

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amilomotide (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Novartis

    • Most Recent Events

    • 22 Sep 2011 Results presented at the 15th World Congress of Psychiatry.
    • 09 Jun 2011 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
    • 16 Jul 2009 Results were presented at the 2009 International Conference on Alzheimer's Disease

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top